pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 3·2 min read
save

STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading data

Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.

Jun 3, 2026·read at STAT ↗

STAT PlusBusiness HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading data Highmark Health is fourth insurer to sue, seeking to overturn arbitration wins Manage alerts for this article Email this article Share this article By Tara BannowJune 3, 2026 Hospitals and Insurance Reporter Tara Bannow[email protected]Tara covers the business of health care. Her stories focus on hospitals, doctors, and how their business practices affect patients — especially when private equity gets involved. She also writes about health insurance and ideas for improving our broken health system.

You can reach Tara on Signal at tarabannow.70. A fourth major health insurer is suing HaloMD over its use of the No Surprises Act’s arbitration process, arguing that the middleman deceived arbitrators by sending them a “sham letter” and misleading price data. Highmark Health, a Pennsylvania-based Blue Cross Blue Shield licensee with over 7 million members, claims in a complaint filed June 1 in U.S.

District Court in Western Pennsylvania that HaloMD and one of its clients, a neuromonitoring provider called Bromedicon, submitted more than 450 ineligible disputes with the company and won more than $3.9 million. Like the three Blue Cross plans before it, Highmark wants those awards tossed and its money returned.Advertisement “Defendants’ scheme is not a good faith attempt to obtain fair reimbursement,” Highmark’s complaint says. “It is a deliberate effort to wrongfully extract inflated payments from Highmark.” STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In health care costs, Health insurance, legal, patients, Physicians, Policy, STAT+ Submit a correction requestReprints Tara Bannow Hospitals and Insurance Reporter Tara covers the business of health care.

Her stories focus on hospitals, doctors, and how their business practices affect patients — especially when private equity gets involved. She also writes about health insurance and ideas for improving our broken health system. You can reach Tara on Signal at tarabannow.70.

Newsletter Unpacking the business — and secretive inner workings — of the U.S. health care industry Recommended The Readout June 3, 2026 STAT Plus: Legend Biotech emerged as a rare market winner First Opinion June 3, 2026 The medical-billing AI arms race between providers and insurance Advertisement Politics June 3, 2026 STAT Plus: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients The Readout June 2, 2026 STAT Plus: Radiopharmaceutical shows promise in post-Pluvicto setting Health Care Inc. Newsletter June 1, 2026 STAT Plus: Medicare’s mum on GLP-1s, and Massachusetts sues United Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
517 words · retrieved Jun 3
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Protara Therapeutics, Inc.7Legend Biotech CorpUltragenyx Pharmaceutical Inc.
drugs
PLUVICTOlutetium Lu 177 vipivotide tetraxetan
topics
Radioligand TherapyRare Disease

related stories

  • Jun 3STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patientsSTAT
  • Jun 4Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this storySTAT
  • Jun 3STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeuticsSTAT
  • Jun 3STAT+: Legend Biotech emerged as a rare market winnerSTAT
  • Aug 4J&J pharma leader to retire; Krystal slumps on gene therapy missBioPharma Dive